Adirondack Trust Company’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-925
| Closed | -$36.7K | – | 561 |
|
|
2026
Q1 | $36.7K | Hold |
925
| – | – | 0.01% | 277 |
|
|
2025
Q4 | $23.1K | Hold |
925
| – | – | 0.01% | 313 |
|
|
2025
Q3 | $22.4K | Hold |
925
| – | – | 0.01% | 333 |
|
|
2025
Q2 | $12.2K | Hold |
925
| – | – | ﹤0.01% | 345 |
|
|
2025
Q1 | $13.3K | Hold |
925
| – | – | 0.01% | 326 |
|
|
2024
Q4 | $15.5K | Hold |
925
| – | – | 0.01% | 320 |
|
|
2024
Q3 | $14.8K | Hold |
925
| – | – | 0.01% | 331 |
|
|
2024
Q2 | $8.35K | Hold |
925
| – | – | ﹤0.01% | 375 |
|
|
2024
Q1 | $10.5K | Hold |
925
| – | – | ﹤0.01% | 355 |
|
|
2023
Q4 | $9.72K | Hold |
925
| – | – | ﹤0.01% | 358 |
|
|
2023
Q3 | $5.98K | Hold |
925
| – | – | ﹤0.01% | 395 |
|
|
2023
Q2 | $7.31K | Hold |
925
| – | – | ﹤0.01% | 363 |
|
|
2023
Q1 | $3.56K | Hold |
925
| – | – | ﹤0.01% | 422 |
|
|
2022
Q4 | $2.86K | Hold |
925
| – | – | ﹤0.01% | 426 |
|
|
2022
Q3 | $4K | Hold |
925
| – | – | ﹤0.01% | 408 |
|
|
2022
Q2 | $5K | Hold |
925
| – | – | ﹤0.01% | 378 |
|
|
2022
Q1 | $8K | Buy |
925
+525
| +131% | +$4.79K | ﹤0.01% | 338 |
|
|
2021
Q4 | $5K | Buy |
+400
| New | +$5.38K | ﹤0.01% | 347 |
|
Adirondack Trust Company's CNTA Position: Q2 2026 in Review
Adirondack Trust Company sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 925 shares — an estimated $36.7K sold.
Adirondack Trust Company first reported a position in CNTA in Q4 2021 and held it in 18 quarters. The position peaked at $36.7K in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Adirondack Trust Company reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Adirondack Trust Company sold 925 Centessa Pharmaceuticals shares in Q2 2026, an estimated $36.7K.
- Adirondack Trust Company first reported a position in Centessa Pharmaceuticals in Q4 2021 and held it in 18 quarters.
- Adirondack Trust Company's Centessa Pharmaceuticals position peaked at $36.7K in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Adirondack Trust Company's 13F filing for Q2 2026, filed 16 Jul 2026.